Revamp Medical

Company Overview

Snapshot

Founded in January 2016 by Lihu Avitov and Rafi Benary, Revamp Medical operates with 11–50 employees. The company has secured funding across three rounds from five investors, totaling $57,000. In July 2020, its DORAYA acute heart failure catheter received FDA breakthrough device designation, marking a significant regulatory milestone.

Business overview

Revamp Medical is dedicated to addressing unmet needs in acute heart failure patients through its innovative catheter-based solution. The company's core product, the DORAYA catheter, is designed to temporarily regulate vascular hemodynamics and improve the efficacy of diuretic therapy in patients with acute heart failure, including those with diuretic resistance. It serves the healthcare market, specifically targeting cardiologists and hospitals within the medical devices and medical treatment & therapeutics sectors.

Strategic signal

In May 2023, Revamp Medical secured Series A funding to advance clinical trials for its DORAYA catheter. This investment signals continued investor confidence in the company's technology and its potential to address critical needs in acute heart failure treatment, paving the way for further product development and market entry.

Company Intelligence Q&A

What is the primary product developed by Revamp Medical?

Revamp Medical's primary product is the DORAYA catheter, a manageable flow-reducing Central Venus Catheter designed to improve the efficacy of diuretic therapy in patients with acute heart failure.

When did Revamp Medical receive FDA Breakthrough Device Designation for its DORAYA catheter?

In July 2020, Revamp Medical's DORAYA acute heart failure catheter received FDA breakthrough device designation.

Which investors participated in Revamp Medical's Series A funding round in May 2023?

In May 2023, Revamp Medical secured Series A funding from investors including.

What is the purpose of the DORAYA catheter?

The DORAYA catheter is designed to be deployed in the infrarenal IVC for up to 12 hours, helping cardiologists temporarily manage venous hemodynamics, central venous pressure, renal afterload, and venous returns in acute heart failure patients.

When was Revamp Medical founded and by whom?

Revamp Medical was founded in January 2016 by Lihu Avitov and Rafi Benary.